Products Affected - Description

• • Cytarabine solution for injection, Pfizer, 100 mg/mL, 20 mL preservative-free vial, 1 count, NDC 61703-0319-22
  • Cytarabine solution for injection, Pfizer, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 61703-0304-36
  • Cytarabine solution for injection, Pfizer, 20 mg/mL, 5 mL preservative-free vial, 5 count, NDC 61703-0305-38
  • Cytarabine solution for injection, Pfizer, 20 mg/mL, 50 mL preservative-free vial, 1 count, NDC 61703-0303-46

Reason for the Shortage

• • Fresenius Kabi has cytarabine injection available.
  • Meitheal has cytarabine injection available.
  • Pfizer has cytarabine injection on shortage due to manufacturing delays. In mid-2026, heavy rains flooded a key manufacturing facility in Gujarat, India.
  • Sagent has cytarabine injection available.

Available Products

• • Cytarabine solution for injection, Fresenius Kabi, 100 mg/mL, 20 mL preservative-free vial, 1 count, NDC 63323-0120-20
  • Cytarabine solution for injection, Meitheal Pharmaceuticals, 100 mg/mL, 20 mL preservative-free vial, 1 count, NDC 71288-0109-20
  • Cytarabine solution for injection, Sagent, 100 mg/mL, 20 mL preservative-free vial, 1 count, NDC 25021-0223-20
  • Cytarabine solution for injection, Sagent, 20 mg/mL, 5 mL preservative-free vial, 5 count, NDC 25021-0229-05

• • Pfizer has cytarabine 20 mg/mL 5 mL, 25 mL, and 50 mL vials in limited supply and the company estimates supply with be depleted before the end of the year. The 100 mg/mL 20 mL vials are also in limited supply and the company estimates supply will be depleted in 1st quarter 2027. Once supply is depleted, product is not expected to be available throughout 2027.

• • Consider evaluating the health-care system's total supply of cytarabine before beginning patients on combination chemotherapy regimens containing cytarabine. If adequate supplies are not available, select an alternative regimen.
  • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for cytarabine.
  • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
  • Refer to the ASHP Infographics on Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/drug-shortages/docs/ASHP-drug-shortages-infographic.pdf?rev=8c909ada5cfb4f05a28d5452eb57dd16
  • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.